Jan 14, 2021 / 03:00PM GMT
Richard Vosser - JPMorgan Chase & Co, Research Division - Senior Analyst
Good morning, good afternoon. Welcome to the 39th JPMorgan Healthcare Conference. I'm Richard Vosser, European pharma analyst with JPMorgan, and it gives me great pleasure to introduce David Loew, CEO of Ipsen for this presentation. (Operator Instructions)
With that, I'd like to say it's a great pleasure to have you with us here, David. And over to you.
David Loew - Ipsen S.A. - CEO & Director
Thank you, Richard, and good morning, good afternoon and good evening, everybody. I'm joined here with Aymeric Le Chatelier, our CFO; and Howard Mayer, our Head of R&D, who are going to also come in once we go into the Q&A section.
Let's go to Slide 2. Before we begin, here is our safe harbor statement, which outlines the routine risks and uncertainties contained within this presentation.
For those of you not so familiar with Ipsen, I have joined Ipsen in July as the new CEO, and we have gone through a deep review and debate on where we want to focus, what
Ipsen SA at JPMorgan Healthcare Conference (Virtual) Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot